Lembas
Lembas commercially develops B2B food-and-supplement ingredients; Lembas Edge is a food-grade peptide that helps the body release fullness-signaling hormone GLP-1.
- Tel Aviv, ILIsrael
Lembas commercially develops B2B food-and-supplement ingredients; Lembas Edge is a food-grade peptide that helps the body release fullness-signaling hormone GLP-1.
hellolembas.comCrawled Nov 4, 2026
Conducted by scientists from Lembas Bio and Tel Aviv University, including Eden Goldfarb, Lucia Adriana Lifshits, Marina Abramova, Daniel Zvi Bar,
Engineering bioactive peptides that pull their weight.
Media coverage highlights Lembas’s work in GLP-1–aligned functional foods and their impact on global food systems and health.
Lembas invites inquiries from partners, investors, and those interested in its next-generation nutrition work.
Lembas is an AI-powered peptide discovery company developing the next generation of functional ingredients for food, beverages, and supplements.
Lembas develops natural, functional foods aligned with GLP-1 biology to support focus, recovery, and longevity.
Lembas Bio’s privacy policy outlines data collection, usage, and security measures to protect user information.
Biotech startup **Lembas** proposes functional foods with peptides as a complementary approach to GLP-1 drugs for weight management. The company highlights an emerging trend where food-based solutions may play a key role in future weight-loss strategies, rather than relying solely on pharmaceutical interventions. This perspective was shared at the **Future Food-Tech San Francisco** event.
Apr 2026FoodNavigator.comNews article
Lembas, an AI-driven Tel Aviv company, secures $3.6 million in pre-seed funding to advance bioactive peptide discovery. The startup leverages artificial intelligence to identify and develop peptide-based solutions. Lembas focuses on applying its technology to potential biomedical applications.
Jun 2025FinSMEsNews article
Lembas, an AI-driven bioactive discovery company, unveils a breakthrough in natural GLP-1 solutions for weight management. The company secures a $3.6 million funding round to advance its food-as-medicine metabolic health platform. This discovery aims to leverage natural compounds for metabolic health applications.
Jun 2025PR NewswireNews article
Lembas introduces a peptide designed to enhance GLP-1 activity as an alternative to weight-loss drugs like Ozempic and Wegovy. The company targets individuals who face accessibility, affordability, or tolerance issues with existing pharmaceutical options. This peptide aims to compete with pharma-driven weight-loss solutions dominating the market.
Jun 2025AgFunderNewsNews article